Methods of treating a deficiency of functional tripeptidyl peptidase I (CLN2) protein
AssigneeUniversity of Medicine and Dentistry of New Jersey
InventorsPeter Lobel, David Sleat
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for treating a patient having disorder characterized by a deficient amount of functional CLN2 protein in the affected cells, which comprises administering to the patient an amount of CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2 protein.
Claims16
A method for treating a patient having a disorder characterized by a deficient amount of functional tripeptidyl peptidase I (CLN2) protein in the affected cells, which comprises administering to the patient an amount of recombinant human CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2 protein, wherein the recombinant human CLN2 protein:
- (a) is an inactive proenzyme;
- and
- (b) is mannose-6-phosphorylated.
Dependencies are inferred from the claim text.